Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03500913 · ClinicalTrials.gov registry record
Adipose Tissue and Serum Inflammation in GH Deficiency
A clinical trial, sponsored by Columbia University.
- Completed
- Registry status
- 19
- Enrollment target
NCT03500913: Completed study, sponsored by Columbia University.
NCT03500913 is a clinical trial that has completed, run by Columbia University. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03500913 has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
Study Summary
This study will examine adipose tissue inflammation and adipokine expression and serum markers of inflammation and adipokine levels in patients with growth hormone (GH) deficiency before and after treatment.
Primary Outcome
Visceral adipose tissue mass as measured by tota body magnetic resonance imaging
Interventions
- DRUG Growth Hormone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-05-19 |
| Est. Completion | 2020-02-20 |
What the finished NCT03500913 record still lists
NCT03500913 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Growth Hormone is the first listed.
NCT03500913 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03500913 about?
NCT03500913 is a clinical study titled "Adipose Tissue and Serum Inflammation in GH Deficiency". This study will examine adipose tissue inflammation and adipokine expression and serum markers of inflammation and adipokine levels in patients with growth hormone (GH) deficiency before and after treatment.
What is the current status of trial NCT03500913?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2019-05-19. Estimated completion is 2020-02-20.
What interventions are being tested in trial NCT03500913?
The interventions under investigation include: Growth Hormone (DRUG).
Who is sponsoring clinical trial NCT03500913?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI